(Wall Street Journal) – Biotech firm sees a growing market, if it can navigate the risks of intellectual-property theft, as well as political pushback in the U.S.

While many Western companies are picking up stakes in China, U.S.-based drugmakers are planting roots. The sales opportunity is huge and growing. But to capitalize on it, firms must navigate fraught relations between the two countries, as well as complicated dynamics inside China and tense politics back home.

Among the knotty issues confronting pharmaceutical companies seeking a valuable piece of the $311 billion market are political pushback in the U.S. and the risk of intellectual-property theft in China. (Read More)